GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » GF Score

Integrated Biopharma (Integrated Biopharma) GF Score : 43/100 (As of Jun. 10, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma GF Score?

Integrated Biopharma has the GF Score of 43, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 7/10
3. Growth Rank : 1/10
4. GF Value Rank : 0/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Integrated Biopharma might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of Integrated Biopharma's GF Score

For the Packaged Foods subindustry, Integrated Biopharma's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrated Biopharma's GF Score Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's GF Score distribution charts can be found below:

* The bar in red indicates where Integrated Biopharma's GF Score falls into.



Integrated Biopharma  (OTCPK:INBP) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.


Integrated Biopharma GF Score Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Integrated Biopharma (Integrated Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
225 Long Avenue, Building 15, Hillside, NJ, USA, 07205
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. It serves the needs of the nutraceutical industry by directly doing business as Chem International Inc. and through its operating subsidiaries; Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc. and MDC Warehousing and Distribution, Inc. The company generates maximum revenue from the Contract Manufacturing segment. The business operates and generates the majority of revenue from the United States.
Executives
Damon Desantis director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe director, 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca director 72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay director, 10 percent owner, officer: Chairman and CEO C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker director STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach director, officer: President and CEO
Glenn Chang director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov director C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva director, officer: Vice President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay director, officer: Vive President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick director C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi officer: Chief Financial Officer 14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis director, 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431